ASCI: a potential for a better tolerability
When ASCI targets antigens that are only found on cancer cells, it is expected that the treatment traces and destroys only cancer cells – leaving normal healthy cells untouched.
For this reason it is hoped that patients treated with ASCI may have relatively few side effects. This will be confirmed in clinical trials.
A large worldwide clinical study commencing 2008 will test how well ASCI treatment works in one type of lung cancer and the level of side effects it may cause.
Are you interested in taking part in a clinical study? Click here.
